



Setting New Standards for Venous Care

March 2024 Investor Presentation

Nasdaq: NVNO
enVVeno.com



Legal Disclaimers

This presentation and any statements of stockholders, directors, employees, representatives and partners of enVveno Medical, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, with respect to our name change, our progress with the VenoValve[®] and the expected timeline related to the SAAVE U.S. pivotal trial, including the timing of beginning patient enrollment, the VenoValve[®]'s ability to fill the unmet medical needs of CVI sufferers and our development of a second device for the treatment of venous disease) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Chronic Venous Insufficiency (CVI) is Caused by the Failure of Valves in the Veins of the Leg

There are Currently No Effective Treatment Options for Deep Venous CVI



Surgical replacement venous valve
Ongoing SAVVE U.S. pivotal trial
Potential U.S. TAM: 2.5 million patients



Non-surgical replacement venous valve
IDE for pivotal trial expected Q4 2024
Potential U.S. TAM: 3.5 million patients

Expect to File PMA Application for VenoValve in Q4 2024

Sufficient Capital to Fund Operations Through the End of 2025


Chronic Venous Insufficiency (CVI)



Learn More

Chronic Venous Insufficiency (CVI)

Occurs as a result of increased venous pressure (venous hypertension) within the veins of the leg, due to failure of valves within the veins





Leads to:

- Reflux – blood flows in the wrong direction
- Blood pooling in the lower leg
- Venous hypertension
- Pain
- Edema
- Ulceration

CVI Patients Need an Effective Treatment


6

 ~2.5M
 ~3.5M
People in the U.S.¹

~\$30k
Spent on wound care
per patient per year²




20-40%
1-Year ulcer
recurrence¹



~\$3B
Direct medical
costs²



~40%
More workdays
missed³



1. Yost, Mary, The Sage Group, Chronic Venous Disease, Epidemiology, Costs, and Consequences, 2016
2. Sachdev, Ulka, et. al. Suppressed Networks of Inflammatory Mediators Characterize Chronic Venous Insufficiency, Journal of Vascular Surgery: Venous and Lymphatic Disorders, May 2018
3. Rice, J. Bradford, Burden of Venous Leg Ulcers in the United States, Journal of Medical Economics, Volume 17, 2014

Deep Venous CVI: Current Standard of Care


7



Compression Garments

Leg Elevation

venoValve




First-In-Class Surgical Replacement Venous Valve

Ongoing U.S. Pivotal Trial

Significant Opportunity with **~2.5 million**
Potential Patients in the U.S.

PMA Application Expected **Q4 2024**



FDA Breakthrough Device Designation

veno valve



View Video

Prospective, Non-Blinded, Single Arm, Multi-Center Study



75 Patients



Across **21 Sites**
in the U.S.

Primary Safety
Endpoint


30 DAYS

Efficacy
Endpoints


180 DAYS

30-Day Device Related Material Adverse Event (MAE)

SAVVE Device Related MAEs N=75
(6 MAEs)




SAVVE Device Related
MAE Severity



Quantitative

FDA: "Totality of Evidence"

Qualitative




One Year Data in Support of PMA




Initial Positive 6-Month Topline Efficacy Data

14


**% of Patients with Clinical Improvement
(Improvement in rVCSS n=69)**




**% of Patients with Clinical Meaningful Benefit
(Improvement in rVCSS n=69)**



**Average rVCSS Point Improvement
Patients with Clinical Meaningful Benefit at
6 Months (n = 51)**



**Average rVCSS Score by CEAP Diagnosis in Patients
with Clinically Meaningful Benefit (N=51)**



Subject A



12 Months

Subject B



Baseline



6 Months

Subject C



Baseline



6 Months




Patient Testimonials From Pivotal Trial



[View Video](#)

enVve




Next-Generation, Non-Surgical Replacement Venous Valve

Transcatheter-based **minimally invasive procedure**

No general anesthesia or overnight **hospital stay**

Significant opportunity with
~3.5 million potential patients in the U.S.

IDE filing for pivotal trial expected **Q4 2024**





[View Video](#)



Corporate Overview

Commercial Manufacturing

21

14,000 square foot facility
in Irvine, CA

Capacity to support at least first
5 years of commercialization

Limited capital investment in plant
and equipment required for
VenoValve commercialization



Financial Overview

22


Cash on Hand Sufficient to Fund Current Operations,
Including Multiple Value Driving Milestones, Through End of 2025



Perceptive Advisors – Lead Investor

Management Team

23



ROBERT BERMAN

Chief Executive Officer, Director

- Former CEO – Anixa Biosciences (Nasdaq:ANIX)
- Former COO Acacia Research Corporation (Nasdaq:ACTG)
- B.S. Wharton, Univ. of Pennsylvania, JD Northwestern Law



DR. MARC GLICKMAN

Senior VP and Chief Medical Officer

- Board Certified Vascular Surgeon
- Director of Vascular Services – Sentara Health Care
- Past President – Vascular Society of America



CRAIG GLYNN

Chief Financial Officer

- Over 30 years financial experience
- M.S. and B.S. Accounting – California State University Northridge
- Member – American Institute of CPAs



DR. HAMED ALAVI

Senior VP and Chief Technology Officer

- Edwards Lifesciences, Medtronic
- PhD Biomedical Engineering – U.C. Irvine
- M.S. Biomedical Engineering, B.S. Mechanical Engineering



KEVIN BELTEAU

VP Clinical

- Clinical operations Medtronic
- MBA – University of South Florida
BS Biomedical Engineering – Texas A&M University
- More than 75 clinical studies for class III medical devices seeking PMA approval

Collective Industry Experience



Board of Directors

24



DR. FRANCIS DUHAY

Director

- Former Chief Medical Officer – Edwards Lifesciences
- Expert in surgical and transcatheter heart valves
- General manager Acendra business unit



DR. SANJAY SHRIVASTAVA

Director

- Business Development – Johnson and Johnson
- 18 years – VP Marketing and Strategy, R&D
- BTG, Medtronic, Abbott Vascular, Edwards Lifesciences



MATTHEW JENUSAITIS

Director

- Chief of Staff and Chief of Innovation and Transformation – UC San Diego Health System
- Former President Boston Scientific – Peripheral Division
- Four successful vascular company exits



BOB GRAY

Director*

- Former Chief Financial Officer – Highmark, Inc.
- Health insurer with over 20 years subscribers
- Rate setting and reimbursement negotiations

*Chairman, Audit Committee

Collective Industry Experience




Upcoming Milestones

25


 = VenoValve

 = enVeno

 ✓ SAVVE: Positive Initial
Topline Efficacy Data

 Begin GLP Study

Q1
2024

 Present Additional
Topline Efficacy Data

Q2
2024

 PMA Eligibility to File for
FDA Approval

 File IDE Application for Pivotal Trial

Q4
2024

“Green Field” Opportunity, Very Large Market

Clinical

Positive Device Related Safety Data
Initial Topline Efficacy – March 2024

Capital

Sufficient capital to fund
operations through end of 2025

Execution

World-class team of executives
and advisors driving execution

Managed Risks



Setting New Standards for Venous Care

Appendix

Cap Table

29

Common Stock Outstanding	13,316,636
Warrants	
Pre-Funded Warrants	2,736,935
Other Warrants	
Exercise Price:	
\$7	3,056,392*
\$7 - \$10	10,793,258
\$10 - \$50	536,830
> \$50	6,000
Total Warrants	14,392,480
Equity Incentive Plan	5,185,276
Total Common Stock, Warrants and Options Outstanding	35,631,327
Total Authorized Shares	250,000,000
Preferred	10,000,000